<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 5, 2000
PATHOGENESIS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 0-27150 91-1542150
(State or other (Commission (IRS Employer
jurisdiction of File No.) Identification No.)
incorporation)
201 Elliott Avenue West, Seattle, Washington 98119
(Address of principal executive offices)
(206) 467-8100
(Registrant's telephone number, including area code)
Not applicable
(Former name or former address, if changes since last report)
<PAGE>
Item 5. Other Events
Annexed hereto as Exhibit 1 is a copy of a press release issued by
PathoGenesis Corporation on June 5, 2000 announcing that PathoGenesis has
engaged advisers to assist in PathoGenesis' efforts to explore strategic
alternatives for enhancing shareholder value.
Item 7. Exhibits
Exhibit Number Description
1 Press Release dated June 5, 2000
2
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: June 5, 2000
PATHOGENESIS CORPORATION
By: /s/ Alan R. Meyer
---------------------------------------
Alan R. Meyer
Executive Vice President and
Chief Financial Officer
3
